Financial Services

After resolving manufacturing hurdles, Camurus' self-administered acromegaly treatment Oclaiz is back on track for US approval, promising new hope for patients.

Facing economic fallout and service crises, over 1,900 municipal leaders will press provincial officials for concrete action at a critical conference.

Major drill results in New Brunswick reveal a rich antimony deposit, a key step in challenging China and Russia's grip on this strategic mineral supply.

Appalachian Dairy Farmers Cooperative announces a landmark management transition to ensure stability and growth for its members in a volatile market.

Akari Therapeutics is advancing a new class of cancer drugs. Its unique PH1 payload kills tumors and activates the immune system, setting up a pivotal 2026.

Health Canada uncovers counterfeit erectile dysfunction drugs in Mississauga, warning of life-threatening dangers and a compromised supply chain.

Newly-formed materials giant Magnera reports Q1 results on Feb 5. Investors eye its path to profitability while the industry watches for key market signals.

Independent retailers saw a 4.5% sales jump in December, with easing inflation offering a bright spot for urban consumers amid economic uncertainty.

The strategic merger creates a vertically integrated supplier, combining advanced forming with precision machining to target aerospace, defense, and automotive.

The oil and gas firm raised its quarterly payout to $0.40/share, rewarding investors and underscoring its financial health and disciplined strategy.

Rigetti Computing pushes back its Cepheus-1-108Q launch to Q1 2026, a move that rattled investors but underscores the quantum industry's tough race for fidelity.

With its first MASH drug a success, Madrigal aims to redefine treatment by combining it with a newly licensed Pfizer asset. Is this the future?

A validated study on LEON's FR-JET® mixer shows it creates highly concentrated, potent mRNA nanoparticles, promising to speed up drug development.

As Encompass Health sets its Q4 earnings date, investors watch to see if the rehab giant can sustain its impressive 2025 growth amid industry pressures.

Modest growth is forecast, but Canada's economy faces a pivotal year as federal stimulus clashes with looming CUSMA renegotiations and U.S. headwinds.

Riding a 50% revenue surge, Rhythm Pharmaceuticals faces a pivotal year with a major FDA decision and key clinical data for its rare obesity treatments.

The Oncology Institute promotes new CIO and CPO, signaling a strategic push into AI-driven care and robust talent management to dominate the market.

KB Home launches its new Somerset community in Victorville, tapping into high demand with personalized, energy-efficient homes priced from the mid-$400,000s.

With the appointment of Dr. Stephen Eck, Flare Therapeutics signals a major push to advance its first-in-class cancer therapies targeting transcription factors.

Vocodia Holdings is acquiring PrivacyPal.ai to combat 'Shadow AI' and solve the 'Fidelity Paradox,' aiming to secure AI use for businesses and individuals.